Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10500156" target="_blank" >RIV/00064165:_____/25:10500156 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10500156
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5LE2-BGw.L" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5LE2-BGw.L</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/13524585251355842" target="_blank" >10.1177/13524585251355842</a>
Alternative languages
Result language
angličtina
Original language name
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials
Original language description
Background: In phase 3 trials, ozanimod reduced brain atrophy and improved cognitive processing speed compared with interferon beta-1a (IFN) in participants with relapsing multiple sclerosis (RMS).Objectives: To assess long-term brain volume changes and associations with clinical/cognitive outcomes during an open-label extension ([OLE] DAYBREAK [NCT02576717]).Methods: Completers of phase 3 "parent" trials were eligible to receive ozanimod 0.92 mg in DAYBREAK. Whole brain, thalamic, and cortical gray matter volumes (WBV, TV, and CGMV, respectively) were analyzed annually.Results: Participants receiving continuous ozanimod had sustained, low rates of WBV loss through OLE month (M)60 (annualized least-squares mean percent change from parent baseline: RADIANCE, -0.27; SUNBEAM, -0.35). Compared with participants switched from IFN, these participants had lower reductions in WBV (parent baseline through OLE M48 [RADIANCE] and OLE M60 [SUNBEAM]). Larger baseline brain volumes were associated with numerically better Symbol Digit Modalities Test scores and lower 3-month confirmed disability progression (CDP) incidence. Annualized TV atrophy <= 1.0% was associated with lower 3-month CDP.Conclusion: This study confirms the sustained efficacy of ozanimod in reducing brain atrophy rates for up to 7 years. Brain volume preservation was associated with faster cognitive processing speed and slower physical disability progression.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Multiple Sclerosis Journal
ISSN
1352-4585
e-ISSN
1477-0970
Volume of the periodical
31
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
1218-1230
UT code for WoS article
001533400700001
EID of the result in the Scopus database
2-s2.0-105012830378